Dyadic International Inc. (NASDAQ:DYAI) Short Interest Up 211.0% in August

Dyadic International Inc. (NASDAQ:DYAI) was the recipient of a large increase in short interest during the month of August. As of August 14th, there was short interest totaling 164,738 shares, an increase of 211.0% from the July 30th total of 52,977 shares. Based on an average daily trading volume, of 206,606 shares, the short-interest ratio is currently 0.8 days. Approximately 0.6% of the company’s shares are short sold.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Bank of America Corp DE lifted its stake in shares of Dyadic International by 16,146.7% during the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after purchasing an additional 26,965 shares in the last quarter. Landscape Capital Management L.L.C. purchased a new stake in shares of Dyadic International during the 3rd quarter valued at about $190,000. Geode Capital Management LLC raised its holdings in shares of Dyadic International by 13.7% during the 4th quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after buying an additional 36,266 shares during the period. Finally, BlackRock Inc. acquired a new position in Dyadic International during the 2nd quarter worth approximately $177,000. 27.95% of the stock is owned by hedge funds and other institutional investors.

Dyadic International Trading Down 4.3%

DYAI traded down $0.03 during trading on Thursday, hitting $0.63. 171,458 shares of the company’s stock were exchanged, compared to its average volume of 179,102. Dyadic International has a 1 year low of $0.62 and a 1 year high of $1.60. The stock has a 50 day moving average price of $0.96 and a 200 day moving average price of $0.85. The firm has a market cap of $23.03 million, a P/E ratio of -2.75 and a beta of 1.12. The company has a current ratio of 1.65, a quick ratio of 1.65 and a debt-to-equity ratio of 4.08.

Dyadic International (NASDAQ:DYAI) last issued its earnings results on Wednesday, August 12th. The biotechnology company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.02). The business had revenue of $0.96 million during the quarter, compared to analysts’ expectations of $1.02 million. Dyadic International had a negative net margin of 201.43% and a negative return on equity of 2,920.31%. As a group, analysts expect that Dyadic International will post -0.15 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings upgraded Dyadic International from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, August 12th. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $3.00.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.